The protocol described in this unit is designed to evaluate the effects of androgenic and antiandrogenic endocrine-disrupting compounds (EDCs) in the castrate-immature male rat. Continuous 10-day exposure of the prepubertal male to chemicals is used to identify androgenic or antiandrogenic activities based on the weights of several androgen-dependent tissues on the day after treatment is ended. Androgen-dependent organ weights and growth, along with kidney, liver, and adrenal weights are measured at necropsy. The androgen-dependent tissues include the ventral prostate, seminal vesicles (with fluid plus coagulating glands), levator ani plus bulbocavernosus muscles, Cowper's glands, and glans penis. Optional measures, which facilitate interpretation of the data when positive effects are detected, include serum testosterone and luteinizing hormone levels. Androgenic chemicals cause increases in one or all of the androgen-dependent tissue weights after being administered by oral gavage or subcutaneously (s.c.) to castrate-immature male rats. Antiandrogenic chemicals cause reductions in androgen-dependent tissue weights after being coadministered with testosterone propionate (s.c.).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/0471140856.tx1609s26 | DOI Listing |
Am J Clin Exp Urol
December 2024
Department of Urology, Icahn School of Medicine at Mount Sinai New York, NY, USA.
Epithelial-mesenchymal transition (EMT) is a dynamic process of lineage plasticity in which epithelial cancer cells acquire mesenchymal traits, enabling them to metastasize to distant organs. This review explores the current understanding of how lineage plasticity and phenotypic reprogramming drive prostate cancer progression to lethal stages, contribute to therapeutic resistance, and highlight strategies to overcome the EMT phenotype within the prostate tumor microenvironment (TME). Emerging evidence reveals that prostate tumor cells can undergo lineage switching, adopting alternative growth pathways in response to anti-androgen therapies and taxane-based chemotherapy.
View Article and Find Full Text PDFNihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Osaka Medical and Pharmaceutical University Faculty of Medicine.
A 70-years-old man with metastatic hormone-sensitive prostate cancer received the apalutamide, an oral androgen receptor signaling inhibitor. On day10 after drug initiation, fever and skin rash appeared on his whole-body surface. He stopped taking the drug on day18 and skin symptoms temporarily improved about 7 days after discontinuation.
View Article and Find Full Text PDFNihon Hinyokika Gakkai Zasshi
January 2025
Department of Urology, Jikei University of Medicine.
(Objective) This study aimed at evaluating the efficacy and safety of upfront docetaxel (DTX) treatment and androgen deprivation therapy (ADT) in male patients with high-volume metastatic castration-sensitive prostate cancer (HV-mCSPC). (Methods) This retrospective study was conducted using the medical records of 30 patients treated for HV-mCSPC by using upfront DTX treatment along with ADT at Atsugi City Hospital between December 2015 and December 2022. The patient characteristics, demographics, oncological outcomes, adverse events, and sequential therapy were evaluated.
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
Department of Oncology and Hematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Backgroud: Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over-expression.
Case: We report the case of a 64-year-old female with extra- and intracranial metastases of SDC with evidence of AR and HER2 overexpression. After progression on first line chemotherapy, was administered neratinib, a pan-Erb2 receptor tyrosine kinase inhibitor.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!